AXSM stock forecast, quote, news & analysis
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Axsome Therapeutics (AXSM) Stock Analysis: Robust Pipeline Catalysts Offset Near-Term Consolidation
Key Takeaways
- Axsome Therapeutics shares have traded in a volatile range over the past 30 days, with the stock roughly flat as of late July 2026, moving from approximately $241.67 to $238.58.
- The FDA accepted Axsome's New Drug Application for AXS-12 (reboxetine) for cataplexy in narcolepsy on July 15, 2026, setting a PDUFA target action date of May 1, 2027.
- Auvelity's commercial launch for agitation associated with Alzheimer's disease began in June 2026, representing a major expansion of the product's addressable market.
- The company initiated two pivotal Phase 3 pediatric ADHD trials (FOCUS-2 and FOCUS-3) for solriamfetol, with top-line data expected in the first half of 2027.
- Analyst consensus remains overwhelmingly bullish, with a Strong Buy rating and an average price target around $281.80, while Q2 2026 earnings are scheduled for August 10, 2026.
Current Market Snapshot
Axsome Therapeutics (AXSM) has demonstrated resilient price action amid a period of consolidation, with shares hovering near the $238 mark as of late July 2026. The stock has experienced notable intra-period swings, touching a high of roughly $252 in early July before pulling back to levels near $221 in mid-July, and subsequently recovering. This range-bound behavior reflects a market that is digesting a series of positive pipeline catalysts while weighing the company's path to sustained profitability. With a market capitalization of approximately $12.1 billion and year-to-date gains exceeding 30%, AXSM continues to command strong investor attention within the CNS biopharmaceutical space.
Axsome Therapeutics (AXSM) Business Overview and Competitive Position
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders. The company markets three FDA-approved products across four indications: Auvelity (dextromethorphan-bupropion) for major depressive disorder and agitation associated with Alzheimer's disease, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan) for acute migraine in adults. Axsome's pipeline spans six product candidates targeting ten high-unmet-need indications including ADHD, binge eating disorder, fibromyalgia, smoking cessation, shift work disorder, schizophrenia, and epilepsy. The company recorded total net product revenue of $191.2 million in the first quarter of 2026, representing 57% year-over-year growth, with gross margins of approximately 93%.
Recent Developments Driving AXSM
Several high-impact developments have shaped AXSM's narrative over the past month. On July 15, the FDA accepted the company's NDA for AXS-12, a highly selective norepinephrine reuptake inhibitor for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. This milestone, combined with the commercial launch of Auvelity in Alzheimer's disease agitation in June 2026, underscores Axsome's execution on its regulatory and commercial strategy. The company expanded its Auvelity sales force to approximately 630 representatives to support the dual-indication launch. Additionally, Axsome initiated patient dosing in the FOCUS-2 and FOCUS-3 Phase 3 trials evaluating solriamfetol in pediatric ADHD, triggering analyst reaffirmations from H.C. Wainwright (Buy, $290 PT) and other firms. During this period, Mizuho Securities reiterated a Buy rating with a $310 price target, and Jefferies maintained its $380 target. The broader biotech sector has also experienced rotation-driven volatility, contributing to AXSM's choppy intra-month trading pattern.
Trending AI Robots
Investors seeking data-driven insights into stocks like Axsome Therapeutics may find value in Tickeron's Trending AI Robots page. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and performance benchmarks. The Trending AI Robots section curates only the top-performing and most relevant bots, making it easier for traders to identify strategies aligned with current market conditions. Each bot operates with distinct parameters — from swing trading to long-term investing — and is backed by transparent historical performance metrics. Whether monitoring CNS biopharma stocks like AXSM or scanning for opportunities in other sectors, this curated view helps investors quickly pinpoint AI-driven tools that match their objectives.
2026 Outlook and What Investors Should Watch
Looking ahead, Axsome's trajectory hinges on several key catalysts. The company will report second-quarter 2026 financial results on August 10, which should provide the first glimpse of Auvelity's Alzheimer's agitation launch metrics and updated revenue trends across all three commercial products. Topline data from the Phase 3 ENGAGE trial of solriamfetol in binge eating disorder is expected in the second half of 2026, representing a major pipeline readout. Investors should also monitor prescription trends for Auvelity in both its MDD and Alzheimer's agitation indications, as well as Symbravo's commercial ramp following its sales force expansion. On the regulatory front, the May 2027 PDUFA date for AXS-12 will remain a focal point. Macroeconomic factors including interest rate policy and sector rotation dynamics could influence biotech valuations broadly. While Axsome remains unprofitable on a GAAP basis, its 57% revenue growth trajectory and expanding commercial footprint suggest a compelling long-term narrative — balanced by the inherent binary risks of clinical trial outcomes and competitive pressures in CNS markets from the likes of Alkermes and Jazz Pharmaceuticals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXSM's Stochastic Oscillator dives oversold zone
The Stochastic Oscillator for AXSM moved into oversold territory on July 31, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXSM advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
AXSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXSM as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
AXSM moved below its 50-day moving average on July 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AXSM crossed bearishly below the 50-day moving average on July 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AXSM entered a downward trend on July 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (204.082) is slightly higher than the industry average of (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (15.480) is also within normal values, averaging (420.906).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology